Bernard M. Fitzharris

Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial

Alexander Eggermont, Christian U. Blank, Mario Mandalà et al. · The Lancet Oncology · 2021 · 364 citations · Full text

Surgical Oncology, Medicine, Melanoma +8

Clinical examination, xeromammography, and fine-needle aspiration cytology in diagnosis of breast tumours.

J. M. Thomas, Bernard M. Fitzharris, W H Redding et al. · BMJ · 1978 · 90 citations · Full text

Breast Oncology, Diagnosis, Gynecology +21

Surveillance for Stage I Non‐seminomatous Germ Cell Tumours of the Testis: the Optimal Protocol Has Not Yet Been Defined

Derek Raghavan, B M Colls, J.A. Levi et al. · British Journal of Urology · 1988 · 86 citations

Carboplatin is ototoxic

Ian Kennedy, Bernard M. Fitzharris, B M Colls et al. · Cancer Chemotherapy and Pharmacology · 1990 · 72 citations

Medicine, Otorhinolaryngology, Toxicology +2

Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial

Andrew Bottomley, Corneel Coens, Justyna Mierzynska et al. · The Lancet Oncology · 2021 · 70 citations · Full text

Health-related Quality-of-life Results, Surgical Oncology, Oncology +9